|1.||Gallick, Gary E: 7 articles (12/2011 - 01/2002)|
|2.||Herynk, Matthew H: 4 articles (01/2007 - 01/2003)|
|3.||Bajo, Ana M: 3 articles (01/2012 - 11/2007)|
|4.||Carmena, María J: 3 articles (01/2012 - 11/2007)|
|5.||Prieto, Juan C: 3 articles (01/2012 - 11/2007)|
|6.||Albini, Adriana: 3 articles (09/2011 - 12/2009)|
|7.||Giordano, Silvia: 3 articles (08/2009 - 06/2005)|
|8.||Lee, Seung-Taek: 3 articles (07/2008 - 04/2002)|
|9.||Kim, Ha-Young: 3 articles (08/2007 - 05/2005)|
|10.||Choi, Jeong-Sun: 3 articles (08/2007 - 05/2005)|
01/01/2015 - "Nintedanib, an inhibitor of tyrosine kinase receptors initially developed for cancer, has been recently approved for the treatment of IPF thanks to the observation that these receptors are also abnormally activated in IPF. "
01/01/2015 - "HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. "
06/01/2014 - "Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells."
05/15/2014 - "Potentially actionable mutations were seen in 104/153 (68%) cancers: i) KRAS/NRAS/BRAF mutations were found in 34% of cancers; ii) mTOR pathway activation was documented by immunohistochemistry in 51% of cases and by mutations in mTOR pathway genes in 19% of cancers; iii) TGF-ß/Smad signaling was altered in 10.5% cancers; iv) mutations in tyrosine kinase receptors were found in 9% cases. "
04/01/2014 - "The expression pattern of the receptors on tumor cells also suggests the targeting of specific angiogenic tyrosine kinase receptors may have direct antitumor activity. "
|2.||Pulmonary Fibrosis (Hamman Rich Syndrome)
08/01/2010 - "Furthermore, quantitative real-time PCR (qRT-PCR) demonstrated that gefitinib inhibited the accumulation of collagens I and III. These results reveal that gefitinib reduces pulmonary fibrosis induced by bleomycin in mice and suggest that administration of small molecule EGFR tyrosine kinase inhibitors has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that targeting tyrosine kinase receptors might be useful for the treatment of pulmonary fibrosis in humans."
02/01/2001 - "Effects of hypoxia/reoxygenation on angiogenic factors and their tyrosine kinase receptors in the rat myocardium."
12/01/2013 - "Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2."
11/01/2014 - "Src kinase, a cytosolic non-receptor protein tyrosine kinase, is linked to cell proliferation and differentiation and is up regulated during hypoxia. "
03/01/2013 - "VEGF up-regulation after hypoxia coincides with expression of its two tyrosine kinase receptors Flt-1(VEGFR-1) and Flk-1 (KDR/VEGFR-2), which are the key mediators of physiological angiogenesis. "
01/01/2000 - "These results suggest a possible role for non-receptor protein tyrosine kinases in propagating signals from G-protein coupled receptors to the activation of immediate early genes such as c-fos during hypoxia."
07/01/2002 - "Because of the reported involvement of neutrophin tyrosine kinase receptors in autocrine differentiation in neuroblastomas, we analyzed cell lines positive for full length or chimeric ALK protein for the presence of phoshotyrosine residues within the intracellular region of ALK. "
05/01/2000 - "Emphasis was placed on neuroblastomas because other tyrosine kinase receptors are expressed in human neuroblastomas. "
04/01/2010 - "To study the correlation and clinical significance of expression of tyrosine-kinase receptors (TrkA and TrkB) and vascular endothelial growth factor (VEGF) in human neuroblastomas. "
04/01/2010 - "The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas."
06/01/2000 - "The aim of the present study was to evaluate the expression of VEGF and of its two high-affinity tyrosine kinase receptors (KDR and Flt-1) in neuroblastoma surgical samples and cell lines. "
08/01/2014 - "Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas."
01/01/1995 - "Differential regulation of neuronal sodium channel expression by endogenous and exogenous tyrosine kinase receptors expressed in rat pheochromocytoma cells."
02/01/1995 - "To determine which substrates must associate with this receptor protein-tyrosine kinase in order to promote neurite outgrowth, we introduced into PC12 pheochromocytoma cells three mutant forms of the beta PDGF receptor that no longer associate with specific substrate proteins. "
02/01/2009 - "This study provides evidence that targeting tyrosine kinase receptors such as the vascular endothelial growth factor pathway and the platelet-derived growth factor-beta receptor may have value in the treatment of VHL-related tumors including pheochromocytoma."
01/01/2014 - "In this study, we found that ionomycin, a Ca²⁺ ionophore, concurrently induced asynchronous neurotransmitter release and phosphorylation of a non-receptor protein tyrosine kinase, proline-rich tyrosine kinase 2 (Pyk2), in clonal rat pheochromocytoma PC12 cells and cerebellar granule cells, whereas introduction of Pyk2 siRNA dramatically suppressed ionomycin-induced neurotransmitter release. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|5.||SU 6668 (SU6668)
|8.||SU 5416 (SU5416)
|10.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)